<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">Recent global data indicate that leishmaniasis has become a major medical and veterinary health concern as documented in many endemic countries (
 <xref rid="bb0135" ref-type="bibr">
  <italic>WHO technical report series.</italic>, 2010
 </xref>; 
 <xref rid="bb0005" ref-type="bibr">Alvar et al., 2012</xref>). Control of this disease is complicated because of the presence of numerous species of vectors and reservoirs (
 <xref rid="bb0010" ref-type="bibr">Ashford, 2000</xref>). Treatment of various clinical and epidemiological forms with pentavalent antimonial agents, as the first- standard drugs, over the past 70Â years, is unsatisfactory. The choice of so many second-line compounds alone or in combination is also very limited. At present, there is no vaccine available (
 <xref rid="bb0100" ref-type="bibr">Noazin et al., 2008</xref>). Therefore, current efforts have been focused on discovering and use of new therapeutic natural agents as they provide rich and potential source of bioactive antileishmanial products.
</p>
